Evolus, Inc. (NASDAQ:EOLS) Holdings Raised by Teacher Retirement System of Texas

Teacher Retirement System of Texas grew its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 19.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,084 shares of the company’s stock after acquiring an additional 2,302 shares during the period. Teacher Retirement System of Texas’ holdings in Evolus were worth $155,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Barclays PLC boosted its position in Evolus by 268.0% during the third quarter. Barclays PLC now owns 93,662 shares of the company’s stock valued at $1,518,000 after purchasing an additional 68,213 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Evolus by 173.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock worth $6,781,000 after purchasing an additional 265,635 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Evolus by 9.8% during the 4th quarter. Principal Financial Group Inc. now owns 33,370 shares of the company’s stock worth $368,000 after purchasing an additional 2,989 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Evolus by 47.0% during the 3rd quarter. Jane Street Group LLC now owns 91,899 shares of the company’s stock valued at $1,489,000 after buying an additional 29,396 shares during the last quarter. Finally, Lord Abbett & CO. LLC grew its stake in shares of Evolus by 23.4% in the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock valued at $16,126,000 after buying an additional 188,685 shares in the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Evolus news, Director Karah Herdman Parschauer sold 12,888 shares of the company’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total value of $167,415.12. Following the sale, the director now directly owns 32,183 shares in the company, valued at $418,057.17. This represents a 28.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $60,147.36. Following the sale, the chief marketing officer now owns 95,671 shares of the company’s stock, valued at $1,268,597.46. This trade represents a 4.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 60,575 shares of company stock worth $794,369 in the last ninety days. Insiders own 6.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on EOLS shares. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Wednesday, March 5th. Barclays raised their price objective on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Wednesday, March 5th.

Evolus Stock Performance

Shares of NASDAQ EOLS opened at $12.22 on Thursday. The company has a market cap of $777.03 million, a P/E ratio of -13.43 and a beta of 0.97. Evolus, Inc. has a 12 month low of $9.25 and a 12 month high of $17.82. The business’s 50 day moving average is $13.62 and its two-hundred day moving average is $13.70. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.